PDF(Pubmed)
Abstract：
Crizotinib is a tyrosine kinase inhibitor that has been found to be effective in the treatment of c-ros oncogene 1-positive non-small cell lung cancer. Although this targeted agent for treating cancer has shown superiority to standard chemotherapy in some ways, this drug has adverse effects, such as the development of renal abscesses. Some associated renal damage may disappear with crizotinib withdrawal. Hence, we present the case of a 58-year-old man with non-small cell lung cancer on crizotinib therapy who developed bilateral renal abnormal space-occupying lesions, successively which were difficult to identify using various imaging methods; even PET-CT highly suspected the right renal masses as malignant. Finally, the right renal lesions were confirmed as renal abscesses by postoperative pathology. The left renal lesion was considered as renal cysts through the lesion disappearing after crizotinib withdrawal. There have been very few reports in this respect, especially proved by various methods and confirmed by postoperative pathology. It is important to recognize this drug-related complication in order to avoid incorrect diagnosis and inadequate therapy. It is necessary to monitor renal changes after taking crizotinib.
摘要：
克唑替尼是一种酪氨酸激酶抑制剂，已发现可有效治疗c-ros癌基因1阳性非小细胞肺癌。尽管这种治疗癌症的靶向药物在某些方面显示出优于标准化疗的优势，这种药物有副作用，如肾脓肿的发展。一些相关的肾损害可能随着克唑替尼的戒断而消失。因此，我们介绍了一个58岁的非小细胞肺癌患者，接受克唑替尼治疗，他出现了双侧肾脏异常占位性病变，连续使用各种成像方法难以识别；甚至PET-CT也高度怀疑右肾肿块为恶性。最后,术后病理证实右肾病变为肾脓肿。通过克唑替尼停药后病变消失，左肾病变被认为是肾囊肿。这方面的报道很少，特别是经各种方法证实并经术后病理证实。重要的是要认识到这种药物相关的并发症，以避免不正确的诊断和不充分的治疗。服用克唑替尼后有必要监测肾脏变化。
